Investigation of the effect of cryoprecipitate (blood plasma product that can help blood to clot) transfusion on coagulation abnormalities after open heart, aortic surgeries

Not Applicable

Completed

• Conditions: patients undergoing elective or emergency aortic surgery involving deep hypothermic circulatory arrest (DHCA) during cardiopulmonary bypass (CPB); Anaesthesiology - Other anaesthesiology; Blood - Clotting disorders; Surgery - Other surgery

• Registration Number: ACTRN12612001063808
• Lead Sponsor: Samsung Medical Center Clinical Research Development Program

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-10-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Elective or emergency aortic surgery involving deep hypothermic circulatory arrest (DHCA) during cardiopulmonary bypass (CPB)

Exclusion Criteria

Patients were excluded from the study if they revealed severe hypofibrinogenemia preoperatively, indicated by serum fibrinogen < 50mg/dl or FIBTEM < 1, or if the patients were not indicated to receive cryoprecipitate transfusion after protamine reversal.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in clot amplitude A10 (amplitude at 10 minutes after clotting initiation) in fibrin-based FIBTEM[10 minutes after cryoprecipitate transfusion]

Secondary Outcome Measures

Name	Time	Method
Changes in clotting time (CT) in extrinsically-activated EXTEM[10 minutes after cryoprecipitate transfusion];Changes in alpha angle in extrinsically-activated EXTEM[10 minutes after cryoprecipitate transfusion];Changes in clot amplitude A10 (amplitude at 10 minutes after clotting initiation) in extrinsically-activated EXTEM[10 minutes after cryoprecipitate transfusion]